8-K
filed May 17, 2024, 7:59 PM ET
ticker CYTK
CIK 0001061983
other material
confidence high
sentiment neutral
materiality 0.25
Cytokinetics director Smith resigns; stockholders approve 300K-share ESPP increase
CYTOKINETICS INC
- Sandford D. Smith resigned from the board effective before the 2024 annual meeting, not due to any disagreement.
- Stockholders approved amendment to ESPP increasing authorized shares by 300,000 to total 1,159,879 shares.
- Robert I. Blum and Robert A. Harrington elected as Class II directors for three-year terms.
- Ernst & Young LLP ratified as independent auditor for 2024; say-on-pay proposal passed advisory vote.
- Approximately 91.97% of eligible shares (96,181,650 votes) represented at the meeting, forming a quorum.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Sandford D. Smith resigned as Director at CYTOKINETICS INC.
- Action
- resigned
- Role
- Director
Exact text from the filing
On May 15, 2024, Sandford D. Smith notified Cytokinetics, Incorporated (the “Company”) of his resignation from the Board of Directors of the Company (the “Board of Directors”), with such resignation effective immediately before the 2024 annual meeting of stockholders of the Company held on May 15, 2024 (the “Annual Meeting”).
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CYTOKINETICS INC shareholders approved Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock..
- Proposal
- equity plan
- Outcome
- passed
Exact text from the filing
Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CYTOKINETICS INC shareholders approved Election of Two Class II Directors.
- Proposal
- director election
- Outcome
- passed
Exact text from the filing
Proposal 1: Election of Two Class II Directors The stockholders elected Robert I. Blum and Robert A. Harrington, M.D. as Class II Directors, each to serve for a three-year term and until their successors are duly elected and qualified or their earlier resignation or removal. The voting for each director was as follows: Name For Withheld Broker Robert I. Blum 87,317,169 2,214,926 6,649,555 Robert A. Harrington, M.D. 78,347,186 11,184,909 6,649,555
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CYTOKINETICS INC shareholders approved Advisory Vote on Executive Compensation.
- Proposal
- say on pay
- Outcome
- passed
Exact text from the filing
Proposal 4: Advisory Vote on Executive Compensation The stockholders approved, on an advisory basis, the compensation of the named executive officers, as disclosed in the 2024 Proxy Statement. The votes were as follows: For Against Abstain Broker Non-Vote 85,814,395 2,927,007 790,693 6,649,555
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CYTOKINETICS INC shareholders approved Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 at the 2024-12-31 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2024-12-31
Exact text from the filing
Proposal 3: Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 The stockholders ratified the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were as follows: For Against Abstain 95,957,265 97,750 126,635
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.